Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
European Journal of Cancer (Oxford, England : 1990)|July 26, 2021
Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201Sachiko Yamamoto, Hisato Kawakami, Takayuki Kii, et al.
Annals of Surgical Oncology|September 4, 2021
Prospective Multicenter Interventional Study of Surgical Resection for Liver Metastasis from Gastric Cancer: R0 Resection Rate, and Operative Morbidity and MortalityKazumasa Fujitani, Yukinori Kurokawa, Atsushi Takeno, et al.
The Oncologist|April 5, 2022
Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)Jin Matsuyama, Tetsuji Terazawa, Masahiro Goto, et al.
Cancers|November 26, 2022
Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable DiseaseHisato Kawakami, Kazuhiro Nishikawa, Toshio Shimokawa, et al.
British Journal of Cancer|February 7, 2024
Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational studyTakuro Saito, Yukinori Kurokawa, Kazumasa Fujitani, et al.
Anticancer Research|July 29, 2026
Long-term Outcomes of OGSG1108: A Supplemental Study of Oral Nutritional Supplementation During Adjuvant S-1 ChemotherapyYoshitomo Yanagimoto, Toshimasa Tsujinaka, Junji Kawada, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 13, 2026
Long-term survival outcomes from a phase II trial of perioperative capecitabine plus oxaliplatin for advanced gastric cancer with extensive lymph node metastases: OGSG 1701Shunji Endo, Yutaka Kimura, Naotoshi Sugimoto, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 30, 2025
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: short-term outcomes of a multicenter, phase II study (OGSG1902)Ryo Tanaka, Shunji Endo, Toshifumi Yamaguchi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|January 21, 2026
Neoadjuvant docetaxel, oxaliplatin, and S-1 therapy for patients with large type 3 or type 4 gastric cancer: final outcomes of a multicenter, phase II study (OGSG 1902)Shunji Endo, Ryo Tanaka, Toshifumi Yamaguchi, et al.
The Oncologist|February 12, 2020
A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)Tetsuji Terazawa, Jin Matsuyama, Masahiro Goto, et al.
Pageof 11